TY - JOUR
T1 - Lipoteichoic acid upregulates plasminogen activator inhibitor-1 expression in parapneumonic effusions
AU - Lee, Kai Ling
AU - Chen, Wei Lin
AU - Chen, Ray Jade
AU - Lai, Kevin S.
AU - Chung, Chi Li
N1 - © 2017 Asian Pacific Society of Respirology.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Background and objective: Parapneumonic effusion (PPE) is commonly caused by Gram-positive bacteria (GPB) and often presents with pleural loculation, which is characterized by overproduction of plasminogen activator inhibitor (PAI)-1. Lipoteichoic acid (LTA), a surface adhesion molecule of GPB, binds to the pleural mesothelium and triggers inflammation. However, the effects of LTA on PAI-1 expression in PPE and underlying mechanisms remain unclear. Methods: Thirty consecutive patients with PPE were enrolled, including uncomplicated culture negative (CN, n = 11), Gram-negative bacteria (GNB, n = 7) and GPB (n = 12) groups stratified by pleural fluid characteristics and bacteriology, and the effusion PAI-1 levels were measured. In addition, human pleural mesothelial cells (PMC) were treated with LTA and the expression of PAI-1 and activation of signalling pathways were assayed. Results: The median levels of PAI-1 were significantly higher in GPB (160.5 ng/mL) and GNB (117.0 ng/mL) groups than in the uncomplicated CN (58.0 ng/mL) group. In human PMC, LTA markedly upregulated PAI-1 mRNA and protein expression and enhanced elaboration of Toll-like receptor 2 (TLR2). Furthermore, LTA increased c-Jun N-terminal kinase (JNK) phosphorylation, induced activating transcription factor 2 (ATF2)/c-Jun nuclear translocation and activated PAI-1 promoter activity. Pretreatment with TLR2 siRNA significantly inhibited LTA-induced JNK phosphorylation and PAI-1 protein expression. Conclusion: Culture-positive PPE, especially that caused by GPB, has a significantly higher level of PAI-1 than uncomplicated CN PPE. LTA upregulates PAI-1 expression through activation of TLR2/JNK/activator protein 1 (AP-1) pathway in human PMC. Better understanding of the modulation of PAI-1 synthesis by LTA in PPE may provide potential therapies for infected pleural effusions.
AB - Background and objective: Parapneumonic effusion (PPE) is commonly caused by Gram-positive bacteria (GPB) and often presents with pleural loculation, which is characterized by overproduction of plasminogen activator inhibitor (PAI)-1. Lipoteichoic acid (LTA), a surface adhesion molecule of GPB, binds to the pleural mesothelium and triggers inflammation. However, the effects of LTA on PAI-1 expression in PPE and underlying mechanisms remain unclear. Methods: Thirty consecutive patients with PPE were enrolled, including uncomplicated culture negative (CN, n = 11), Gram-negative bacteria (GNB, n = 7) and GPB (n = 12) groups stratified by pleural fluid characteristics and bacteriology, and the effusion PAI-1 levels were measured. In addition, human pleural mesothelial cells (PMC) were treated with LTA and the expression of PAI-1 and activation of signalling pathways were assayed. Results: The median levels of PAI-1 were significantly higher in GPB (160.5 ng/mL) and GNB (117.0 ng/mL) groups than in the uncomplicated CN (58.0 ng/mL) group. In human PMC, LTA markedly upregulated PAI-1 mRNA and protein expression and enhanced elaboration of Toll-like receptor 2 (TLR2). Furthermore, LTA increased c-Jun N-terminal kinase (JNK) phosphorylation, induced activating transcription factor 2 (ATF2)/c-Jun nuclear translocation and activated PAI-1 promoter activity. Pretreatment with TLR2 siRNA significantly inhibited LTA-induced JNK phosphorylation and PAI-1 protein expression. Conclusion: Culture-positive PPE, especially that caused by GPB, has a significantly higher level of PAI-1 than uncomplicated CN PPE. LTA upregulates PAI-1 expression through activation of TLR2/JNK/activator protein 1 (AP-1) pathway in human PMC. Better understanding of the modulation of PAI-1 synthesis by LTA in PPE may provide potential therapies for infected pleural effusions.
KW - lipoteichoic acid
KW - parapneumonic effusion
KW - plasminogen activator inhibitor
KW - pleural mesothelial cell
KW - Toll-like receptor
KW - Up-Regulation/drug effects
KW - Plasminogen Activator Inhibitor 1/genetics
KW - Humans
KW - Middle Aged
KW - Male
KW - Pleural Effusion/metabolism
KW - Aged, 80 and over
KW - Adult
KW - Female
KW - Cell Culture Techniques
KW - Pleura/cytology
KW - Epithelial Cells/metabolism
KW - Activating Transcription Factor 2/metabolism
KW - Gram-Negative Bacteria
KW - JNK Mitogen-Activated Protein Kinases/metabolism
KW - Lipopolysaccharides/pharmacology
KW - Gram-Positive Bacteria
KW - Teichoic Acids/pharmacology
KW - Toll-Like Receptor 2/genetics
KW - Signal Transduction/drug effects
KW - RNA, Messenger/metabolism
KW - Transcription Factor AP-1/metabolism
KW - Aged
KW - Phosphorylation/drug effects
UR - http://www.scopus.com/inward/record.url?scp=85036586167&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85036586167&partnerID=8YFLogxK
U2 - 10.1111/resp.13148
DO - 10.1111/resp.13148
M3 - Article
C2 - 28836366
AN - SCOPUS:85036586167
SN - 1323-7799
VL - 23
SP - 89
EP - 95
JO - Respirology
JF - Respirology
IS - 1
ER -